Cargando…
Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force
Timely and accurate diagnosis of Alzheimer’s disease (AD) in clinical practice remains challenging. PET and CSF biomarkers are the most widely used biomarkers to aid diagnosis in clinical research but present limitations for clinical practice (i.e., cost, accessibility). Emerging blood-based markers...
Autores principales: | Angioni, D., Delrieu, J., Hansson, O., Fillit, H., Aisen, P., Cummings, J., Sims, J.R., Braunstein, J.B., Sabbagh, M., Bittner, T., Pontecorvo, M., Bozeat, S., Dage, J.L., Largent, E., Mattke, S., Correa, O., Robledo, L.M. Gutierrez, Baldivieso, V., Willis, D.R., Atri, A., Bateman, R.J., Ousset, P-J., Vellas, B., Weiner, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683846/ https://www.ncbi.nlm.nih.gov/pubmed/36281661 http://dx.doi.org/10.14283/jpad.2022.85 |
Ejemplares similares
-
Non-Amyloid Approaches to Disease Modification for Alzheimer’s Disease: An EU/US CTAD Task Force Report
por: Gauthier, Serge, et al.
Publicado: (2020) -
Tackling a Major Deficiency of Diversity in Alzheimer’s Disease Therapeutic Trials: An CTAD Task Force Report
por: Raman, Rema, et al.
Publicado: (2022) -
Platform Trials to Expedite Drug Development in Alzheimer’s Disease: A Report from the EU/US CTAD Task Force
por: Aisen, P. S., et al.
Publicado: (2021) -
Using Digital Tools to Advance Alzheimer’s Drug Trials During a Pandemic: The EU/US CTAD Task Force
por: Kaye, Jeffrey, et al.
Publicado: (2021) -
CTAD as a universal anticoagulant
por: Yokota, M., et al.
Publicado: (2003)